Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3321367 · 1 trial · 1 indication
Dose Limiting Toxicity (DLT) is defined as an adverse event (AE) that meets protocol defined DLT criteria during cycle 1 and is at least possibly related to study drug.
| Arm | Type | Description |
|---|---|---|
| LY3321367 Dose Escalation | EXPERIMENTAL | LY3321367 given intravenously (IV). |
| LY3321367 + LY3300054 Dose Escalation | EXPERIMENTAL | LY3321367 and LY3300054 given IV. |
| LY3321367 Dose Expansion | EXPERIMENTAL | LY3321367 given IV. |
| LY3321367 + LY3300054 Dose Expansion | EXPERIMENTAL | LY3321367 and LY3300054 given IV. |
| Japanese Arm D LY3321367 | EXPERIMENTAL | LY3321367 given IV. |
| Japanese Arm E LY3300054 | EXPERIMENTAL | LY3300054 given IV. |
| Japanese Arm F LY3321367 + LY3300054 | EXPERIMENTAL | LY3321367 and LY3300054 given IV. |
| Name | Type | Description |
|---|---|---|
| LY3321367 | DRUG | Administered IV |
| LY3300054 | DRUG | Administered IV |
Inclusion Criteria: * For Ph1a monotherapy and combination cohorts, histologic or cytologic confirmation of advanced solid tumor. * For Phase 1a and 1b, prior PD-1 or PD-L1 therapy or other immunotherapy is allowed, if the following criteria are met: * Must not have experienced a toxicity that l...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
LY3321367 is an investigational small molecule being studied for the treatment of solid tumors. It is intended for patients with advanced relapsed or refractory solid tumors, meaning cancers that have not responded to prior treatment or have returned. The drug is currently in Phase 1 clinical development.
LY3321367 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker symbol LLY. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with advanced solid tumors.
LY3321367 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The Phase 1 trial has been completed, and the drug is not yet available for commercial use.
LY3321367 has been studied in one clinical trial with the identifier NCT03099109. This Phase 1 study evaluated LY3321367 alone or in combination with LY3300054 in participants with advanced relapsed or refractory solid tumors. The trial enrolled 209 participants and has been completed.
No, LY3321367 and LY3300054 are different drugs. LY3321367 is the investigational drug being studied, while LY3300054 is a separate agent that was tested in combination with LY3321367 in the clinical trial NCT03099109. The trial evaluated LY3321367 alone or with LY3300054 in patients with advanced solid tumors.